{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T22:55:38Z","timestamp":1788303338446,"version":"build-2803163510"},"reference-count":170,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T00:00:00Z","timestamp":1684454400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007567","name":"City University of Hong Kong","doi-asserted-by":"publisher","award":["7005614"],"award-info":[{"award-number":["7005614"]}],"id":[{"id":"10.13039\/100007567","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007567","name":"City University of Hong Kong","doi-asserted-by":"publisher","award":["7005829"],"award-info":[{"award-number":["7005829"]}],"id":[{"id":"10.13039\/100007567","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007567","name":"City University of Hong Kong","doi-asserted-by":"publisher","award":["9211315"],"award-info":[{"award-number":["9211315"]}],"id":[{"id":"10.13039\/100007567","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017649","name":"Pneumoconiosis Compensation Fund Board","doi-asserted-by":"publisher","award":["7005614"],"award-info":[{"award-number":["7005614"]}],"id":[{"id":"10.13039\/501100017649","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017649","name":"Pneumoconiosis Compensation Fund Board","doi-asserted-by":"publisher","award":["7005829"],"award-info":[{"award-number":["7005829"]}],"id":[{"id":"10.13039\/501100017649","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017649","name":"Pneumoconiosis Compensation Fund Board","doi-asserted-by":"publisher","award":["9211315"],"award-info":[{"award-number":["9211315"]}],"id":[{"id":"10.13039\/501100017649","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>P53 plays a key role in protecting the human genome from DNA-related mutations; however, it is one of the most frequently mutated genes in cancer. The P53 family members p63 and p73 were also shown to play important roles in cancer development and progression. Currently, there are various organic molecules from different structural classes of compounds that could reactivate the function of wild-type p53, degrade or inhibit mutant p53, etc. It was shown that: (1) the function of the wild-type p53 protein was dependent on the presence of Zn atoms, and (2) Zn supplementation restored the altered conformation of the mutant p53 protein. This prompted us to question whether the dependence of p53 on Zn and other metals might be used as a cancer vulnerability. This review article focuses on the role of different metals in the structure and function of p53, as well as discusses the effects of metal complexes based on Zn, Cu, Fe, Ru, Au, Ag, Pd, Pt, Ir, V, Mo, Bi and Sn on the p53 protein and p53-associated signaling.<\/jats:p>","DOI":"10.3390\/cancers15102834","type":"journal-article","created":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T09:23:10Z","timestamp":1684488190000},"page":"2834","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Metal-Based Anticancer Complexes and p53: How Much Do We Know?"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-3043-5865","authenticated-orcid":false,"given":"Samah Mutasim","family":"Alfadul","sequence":"first","affiliation":[{"name":"Drug Discovery Lab, Department of Chemistry, City University of Hong Kong, 83 Tat Chee Avenue, Hong Kong SAR 999077, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Egor M.","family":"Matnurov","sequence":"additional","affiliation":[{"name":"Drug Discovery Lab, Department of Chemistry, City University of Hong Kong, 83 Tat Chee Avenue, Hong Kong SAR 999077, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander E.","family":"Varakutin","sequence":"additional","affiliation":[{"name":"Drug Discovery Lab, Department of Chemistry, City University of Hong Kong, 83 Tat Chee Avenue, Hong Kong SAR 999077, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2009-7837","authenticated-orcid":false,"given":"Maria V.","family":"Babak","sequence":"additional","affiliation":[{"name":"Drug Discovery Lab, Department of Chemistry, City University of Hong Kong, 83 Tat Chee Avenue, Hong Kong SAR 999077, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,5,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/s41580-019-0110-x","article-title":"The multiple mechanisms that regulate p53 activity and cell fate","volume":"20","author":"Hafner","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/358015a0","article-title":"Cancer. p53, guardian of the genome","volume":"358","author":"Lane","year":"1992","journal-title":"Nature"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/sj.onc.1201946","article-title":"Excision of mismatched nucleotides from DNA: A potential mechanism for enhancing DNA replication fidelity by the wild-type p53 protein","volume":"17","author":"Huang","year":"1998","journal-title":"Oncogene"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"5129","DOI":"10.1038\/onc.2012.640","article-title":"Senescence and aging: The critical roles of p53","volume":"32","author":"Rufini","year":"2013","journal-title":"Oncogene"},{"key":"ref_5","first-page":"2851","article-title":"p53 cellular tumor antigen: Analysis of mRNA levels in normal adult tissues, embryos, and tumors","volume":"5","author":"Rogel","year":"1985","journal-title":"Mol. Cell. Biol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S1044-579X(02)00099-8","article-title":"The p53-Mdm2 module and the ubiquitin system","volume":"13","author":"Michael","year":"2003","journal-title":"Semin. Cancer Biol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1093\/emboj\/18.1.22","article-title":"Association of p19(ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53","volume":"18","author":"Honda","year":"1999","journal-title":"EMBO J."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1101\/gad.7.7a.1126","article-title":"The p53-mdm-2 autoregulatory feedback loop","volume":"7","author":"Wu","year":"1993","journal-title":"Genes Dev."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1101\/gad.4.1.1","article-title":"p53: Oncogene or anti-oncogene?","volume":"4","author":"Lane","year":"1990","journal-title":"Genes Dev."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Olivier, M., Hollstein, M., and Hainaut, P. (2010). TP53 mutations in human cancers: Origins, consequences, and clinical use. Cold Spring Harb. Perspect. Biol., 2.","DOI":"10.1101\/cshperspect.a001008"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/cdd.2017.180","article-title":"Why are there hotspot mutations in the TP53 gene in human cancers?","volume":"25","author":"Baugh","year":"2018","journal-title":"Cell Death Differ."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/nature12634","article-title":"Mutational landscape and significance across 12 major cancer types","volume":"502","author":"Kandoth","year":"2013","journal-title":"Nature"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1002\/humu.22552","article-title":"TP53 mutations in human cancer: Database reassessment and prospects for the next decade","volume":"35","author":"Leroy","year":"2014","journal-title":"Hum. Mutat."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Wasylishen, A.R., and Lozano, G. (2016). Attenuating the p53 Pathway in Human Cancers: Many Means to the Same End. Cold Spring Harb. Perspect. Med., 6.","DOI":"10.1101\/cshperspect.a026211"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/nrc.2017.109","article-title":"Targeting mutant p53 for efficient cancer therapy","volume":"18","author":"Bykov","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1093\/jmcb\/mjaa040","article-title":"Gain-of-function mutant p53 in cancer progression and therapy","volume":"12","author":"Zhang","year":"2020","journal-title":"J. Mol. Cell Biol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.cell.2004.11.004","article-title":"Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome","volume":"119","author":"Olive","year":"2004","journal-title":"Cell"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"6658","DOI":"10.1158\/1078-0432.CCR-11-0046","article-title":"Disruptive TP53 mutation is associated with aggressive disease characteristics in an orthotopic murine model of oral tongue cancer","volume":"17","author":"Sano","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1002\/ijc.23317","article-title":"Mutant p53(R270H) gain of function phenotype in a mouse model for oncogene-induced mammary carcinogenesis","volume":"122","author":"Heinlein","year":"2008","journal-title":"Int. J. Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1073\/pnas.0908428107","article-title":"Mutant p53 drives metastasis and overcomes growth arrest\/senescence in pancreatic cancer","volume":"107","author":"Morton","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1007\/s00018-003-3304-4","article-title":"The common and distinct target genes of the p53 family transcription factors","volume":"61","author":"Harms","year":"2004","journal-title":"Cell Mol. Life Sci."},{"key":"ref_22","first-page":"2387","article-title":"Two critical hydrophobic amino acids in the N-terminal domain of the p53 protein are required for the gain of function phenotypes of human p53 mutants","volume":"10","author":"Lin","year":"1995","journal-title":"Oncogene"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1093\/nar\/gkn044","article-title":"C-terminal diversity within the p53 family accounts for differences in DNA binding and transcriptional activity","volume":"36","author":"Sauer","year":"2008","journal-title":"Nucleic Acids Res"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1242\/jcs.113.10.1661","article-title":"The p53\/p63\/p73 family of transcription factors: Overlapping and distinct functions","volume":"113","author":"Levrero","year":"2000","journal-title":"J. Cell Sci."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s12035-011-8172-6","article-title":"p73: A Multifunctional Protein in Neurobiology","volume":"43","author":"Killick","year":"2011","journal-title":"Mol. Neurobiol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Logotheti, S., Richter, C., Murr, N., Spitschak, A., Marquardt, S., and P\u00fctzer, B.M. (2021). Mechanisms of Functional Pleiotropy of p73 in Cancer and Beyond. Front. Cell Dev. Biol., 9.","DOI":"10.3389\/fcell.2021.737735"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Rozenberg, J.M., Zvereva, S., Dalina, A., Blatov, I., Zubarev, I., Luppov, D., Bessmertnyi, A., Romanishin, A., Alsoulaiman, L., and Kumeiko, V. (2021). Dual Role of p73 in Cancer Microenvironment and DNA Damage Response. Cells, 10.","DOI":"10.3390\/cells10123516"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/19539","article-title":"p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development","volume":"398","author":"Yang","year":"1999","journal-title":"Nature"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/19531","article-title":"p63 is a p53 homologue required for limb and epidermal morphogenesis","volume":"398","author":"Mills","year":"1999","journal-title":"Nature"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Zhou, H., and Aberdam, D. (2013). A step closer toward therapies for p63-related disorders. Rare Dis., 1.","DOI":"10.4161\/rdis.24247"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s12307-012-0116-9","article-title":"Role of p63 in Development, Tumorigenesis and Cancer Progression","volume":"5","author":"Bergholz","year":"2012","journal-title":"Cancer Microenviron."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1038\/cdd.2011.81","article-title":"p63 is a suppressor of tumorigenesis and metastasis interacting with mutant p53","volume":"18","author":"Melino","year":"2011","journal-title":"Cell Death Differ."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1002\/cncr.32053","article-title":"Activating p53 family member TAp63: A novel therapeutic strategy for targeting p53-altered tumors","volume":"125","author":"Gunaratne","year":"2019","journal-title":"Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s10549-019-05435-1","article-title":"COTI-2 reactivates mutant p53 and inhibits growth of triple-negative breast cancer cells","volume":"179","author":"Synnott","year":"2020","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"5650","DOI":"10.1158\/1078-0432.CCR-19-0096","article-title":"COTI-2, A Novel Thiosemicarbazone Derivative, Exhibits Antitumor Activity in HNSCC through p53-dependent and -independent Mechanisms","volume":"25","author":"Lindemann","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-021-01169-0","article-title":"Targeting mutant p53 for cancer therapy: Direct and indirect strategies","volume":"14","author":"Hu","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1146\/annurev-cancerbio-030518-055455","article-title":"Targeting Therapies for the p53 Protein in Cancer Treatments","volume":"3","author":"Levine","year":"2019","journal-title":"Annu. Rev. Cancer Biol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1158\/1078-0432.CCR-15-0481","article-title":"Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia","volume":"22","author":"Andreeff","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1126\/science.8023157","article-title":"Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations","volume":"265","author":"Cho","year":"1994","journal-title":"Science"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0065-230X(06)97001-8","article-title":"Structural biology of the tumor suppressor p53 and cancer-associated mutants","volume":"97","author":"Joerger","year":"2007","journal-title":"Adv. Cancer Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1021\/bi026635n","article-title":"Structure, Function, and Aggregation of the Zinc-Free form of the p53 DNA Binding Domain","volume":"42","author":"Butler","year":"2003","journal-title":"Biochemistry"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1038\/sj.onc.1203434","article-title":"Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: Definition of mutant states for rescue in cancer therapy","volume":"19","author":"Bullock","year":"2000","journal-title":"Oncogene"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1039\/c003915b","article-title":"The missing Zinc: p53 misfolding and cancer","volume":"2","author":"Loh","year":"2010","journal-title":"Metallomics"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1101\/gad.7.12b.2556","article-title":"The DNA-binding domain of p53 contains the four conserved regions and the major mutation hot spots","volume":"7","author":"Pavletich","year":"1993","journal-title":"Genes Dev."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1038\/sj.onc.1210291","article-title":"Structure\u2013function\u2013rescue: The diverse nature of common p53 cancer mutants","volume":"26","author":"Joerger","year":"2007","journal-title":"Oncogene"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1101\/gad.190678.112","article-title":"Mutant p53: One name, many proteins","volume":"26","author":"Prives","year":"2012","journal-title":"Genes Dev."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Kogan, S., and Carpizo, D.R. (2018). Zinc Metallochaperones as Mutant p53 Reactivators: A New Paradigm in Cancer Therapeutics. Cancers, 10.","DOI":"10.3390\/cancers10060166"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1124\/mol.114.097550","article-title":"Synthetic metallochaperone ZMC1 rescues mutant p53 conformation by transporting zinc into cells as an ionophore","volume":"87","author":"Blanden","year":"2015","journal-title":"Mol. Pharmacol."},{"key":"ref_49","first-page":"1739","article-title":"A structural role for metal ions in the \u201cwild-type\u201d conformation of the tumor suppressor protein p53","volume":"53","author":"Hainaut","year":"1993","journal-title":"Cancer Res."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Chen, Y., Gao, T., Wang, Y., and Yang, G. (2017). Investigating the Influence of Magnesium Ions on p53-DNA Binding Using Atomic Force Microscopy. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18071585"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"5227","DOI":"10.1038\/sj.onc.1203907","article-title":"Metalloregulation of the tumor suppressor protein p53: Zinc mediates the renaturation of p53 after exposure to metal chelators in vitro and in intact cells","volume":"19","author":"Richard","year":"2000","journal-title":"Oncogene"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1021\/bi062106y","article-title":"Zn2+-dependent misfolding of the p53 DNA binding domain","volume":"46","author":"Butler","year":"2007","journal-title":"Biochemistry"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Garufi, A., Trisciuoglio, D., Cirone, M., and D\u2019Orazi, G. (2016). ZnCl2 sustains the adriamycin-induced cell death inhibited by high glucose. Cell Death Dis., 7.","DOI":"10.1038\/cddis.2016.178"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.4161\/cc.10.10.15642","article-title":"Restoring p53 active conformation by zinc increases the response of mutant p53 tumor cells to anticancer drugs","volume":"10","author":"Puca","year":"2011","journal-title":"Cell Cycle"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Cirone, M., Garufi, A., Di Renzo, L., Granato, M., Faggioni, A., and D\u2019Orazi, G. (2013). Zinc supplementation is required for the cytotoxic and immunogenic effects of chemotherapy in chemoresistant p53-functionally deficient cells. Oncoimmunology, 2.","DOI":"10.4161\/onci.26198"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Garufi, A., Pistritto, G., D\u2019Orazi, V., Cirone, M., and D\u2019Orazi, G. (2022). The Impact of NRF2 Inhibition on Drug-Induced Colon Cancer Cell Death and p53 Activity: A Pilot Study. Biomolecules, 12.","DOI":"10.3390\/biom12030461"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Garufi, A., Ubertini, V., Mancini, F., D\u2019Orazi, V., Baldari, S., Moretti, F., Bossi, G., and D\u2019Orazi, G. (2015). The beneficial effect of Zinc(II) on low-dose chemotherapeutic sensitivity involves p53 activation in wild-type p53-carrying colorectal cancer cells. J. Exp. Clin. Cancer Res., 34.","DOI":"10.1186\/s13046-015-0206-x"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.ccr.2012.03.042","article-title":"Allele-Specific p53 Mutant Reactivation","volume":"21","author":"Yu","year":"2012","journal-title":"Cancer Cell"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"8879","DOI":"10.18632\/oncotarget.2432","article-title":"Small molecule restoration of wildtype structure and function of mutant p53 using a novel zinc-metallochaperone based mechanism","volume":"5","author":"Yu","year":"2014","journal-title":"Oncotarget"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"4575","DOI":"10.1021\/ja066690+","article-title":"Binding of a Single Zinc Ion to One Subunit of Copper\u2212Zinc Superoxide Dismutase Apoprotein Substantially Influences the Structure and Stability of the Entire Homodimeric Protein","volume":"129","author":"Potter","year":"2007","journal-title":"J. Am. Chem. Soc."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1021\/ic102294u","article-title":"One Octarepeate Expansion to the Human Prion Protein Alters Both the Zn2+ and Cu2+ Coordination Environments within the Octarepeate Domain","volume":"50","author":"Shearer","year":"2011","journal-title":"Inorg. Chem."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1016\/j.drudis.2015.07.006","article-title":"Reactivating mutant p53 using small molecules as zinc metallochaperones: Awakening a sleeping giant in cancer","volume":"20","author":"Blanden","year":"2015","journal-title":"Drug Discov. Today"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"5271","DOI":"10.1021\/jm900552r","article-title":"Thiosemicarbazones from the Old to New: Iron Chelators That Are More Than Just Ribonucleotide Reductase Inhibitors","volume":"52","author":"Yu","year":"2009","journal-title":"J. Med. Chem."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1021\/tx700039c","article-title":"Future of toxicology--Iron chelators and differing modes of action and toxicity: The changing face of iron chelation therapy","volume":"20","author":"Kalinowski","year":"2007","journal-title":"Chem. Res. Toxicol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"E562","DOI":"10.1002\/ijc.26441","article-title":"Zinc supplementation augments in vivo antitumor effect of chemotherapy by restoring p53 function","volume":"131","author":"Margalit","year":"2012","journal-title":"Int. J. Cancer"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.yexcr.2008.10.018","article-title":"Restoring wtp53 activity in HIPK2 depleted MCF7 cells by modulating metallothionein and zinc","volume":"315","author":"Puca","year":"2009","journal-title":"Exp. Cell Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"3707","DOI":"10.1158\/0008-5472.CAN-07-6776","article-title":"Reversible dysfunction of wild-type p53 following homeodomain-interacting protein kinase-2 knockdown","volume":"68","author":"Puca","year":"2008","journal-title":"Cancer Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"4505","DOI":"10.1158\/1078-0432.CCR-18-0822","article-title":"Zinc Metallochaperones Reactivate Mutant p53 Using an ON\/OFF Switch Mechanism: A New Paradigm in Cancer Therapeutics","volume":"24","author":"Yu","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Garufi, A., Trisciuoglio, D., Porru, M., Leonetti, C., Stoppacciaro, A., D\u2019Orazi, V., Avantaggiati, M., Crispini, A., Pucci, D., and D\u2019Orazi, G. (2013). A fluorescent curcumin-based Zn(II)-complex reactivates mutant (R175H and R273H) p53 in cancer cells. J. Exp. Clin. Cancer Res., 32.","DOI":"10.1186\/1756-9966-32-72"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Garufi, A., Pucci, D., D\u2019Orazi, V., Cirone, M., Bossi, G., Avantaggiati, M.L., and D\u2019Orazi, G. (2014). Degradation of mutant p53H175 protein by Zn(II) through autophagy. Cell Death Dis., 5.","DOI":"10.1038\/cddis.2014.217"},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Garufi, A., Federici, G., Gilardini Montani, M.S., Crispini, A., Cirone, M., and D\u2019Orazi, G. (2020). Interplay between Endoplasmic Reticulum (ER) Stress and Autophagy Induces Mutant p53H273 Degradation. Biomolecules, 10.","DOI":"10.3390\/biom10030392"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"3734","DOI":"10.1016\/j.ejmech.2011.05.039","article-title":"Non-substituted N-heteroaromatic selenosemicarbazone metal complexes induce apoptosis in cancer cells via activation of mitochondrial pathway","volume":"46","author":"Zec","year":"2011","journal-title":"Eur. J. Med. Chem."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.ajps.2022.07.003","article-title":"Zinc-doped Prussian blue nanoparticles for mutp53-carrying tumor ion interference and photothermal therapy","volume":"17","author":"Jin","year":"2022","journal-title":"Asian J. Pharm. Sci."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Qian, J., Zhang, W., Wei, P., Yao, G., Yi, T., Zhang, H., Ding, H., Huang, X., Wang, M., and Song, Y. (2020). Enhancing Chemotherapy of p53-Mutated Cancer through Ubiquitination-Dependent Proteasomal Degradation of Mutant p53 Proteins by Engineered ZnFe-4 Nanoparticles. Adv. Funct. Mater., 30.","DOI":"10.1002\/adfm.202001994"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"5699","DOI":"10.1128\/MCB.17.10.5699","article-title":"Regulation of p53 by metal ions and by antioxidants: Dithiocarbamate down-regulates p53 DNA-binding activity by increasing the intracellular level of copper","volume":"17","author":"Verhaegh","year":"1997","journal-title":"Mol. Cell. Biol."},{"key":"ref_76","first-page":"27","article-title":"Modulation by copper of p53 conformation and sequence-specific DNA binding: Role for Cu(II)\/Cu(I) redox mechanism","volume":"10","author":"Hainaut","year":"1995","journal-title":"Oncogene"},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Babak, M.V., and Ahn, D. (2021). Modulation of Intracellular Copper Levels as the Mechanism of Action of Anticancer Copper Complexes: Clinical Relevance. Biomedicines, 9.","DOI":"10.3390\/biomedicines9080852"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"797s","DOI":"10.1093\/ajcn\/63.5.797","article-title":"Copper biochemistry and molecular biology","volume":"63","author":"Linder","year":"1996","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Yadav, A.K., Singh, V., Kushwaha, R., Dolui, D., Rai, R., Dhar, P., Dutta, A., Koch, B., and Banerjee, S. (2023). Polypyridyl CoII-Curcumin Complexes as Photoactivated Anticancer and Antibacterial Agents. ChemBioChem.","DOI":"10.1002\/cbic.202300033"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1126\/science.abf0529","article-title":"Copper induces cell death by targeting lipoylated TCA cycle proteins","volume":"375","author":"Tsvetkov","year":"2022","journal-title":"Science"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1038\/s41418-023-01125-0","article-title":"Cuproptosis: p53-regulated metabolic cell death?","volume":"30","author":"Xiong","year":"2023","journal-title":"Cell Death Differ."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1089\/ars.2010.3663","article-title":"Anticancer activity of metal complexes: Involvement of redox processes","volume":"15","author":"Jungwirth","year":"2011","journal-title":"Antioxid. Redox Signal."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Bulatov, E., Sayarova, R., Mingaleeva, R., Miftakhova, R., Gomzikova, M., Ignatyev, Y., Petukhov, A., Davidovich, P., Rizvanov, A., and Barlev, N.A. (2018). Isatin-Schiff base-copper (II) complex induces cell death in p53-positive tumors. Cell Death Discov., 4.","DOI":"10.1038\/s41420-018-0120-z"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.ejmech.2018.09.020","article-title":"Designing anticancer copper(II) complexes by optimizing 2-pyridine-thiosemicarbazone ligands","volume":"158","author":"Deng","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.ejmech.2016.10.041","article-title":"Synthesis of copper and zinc 2-(pyridin-2-yl)imidazo[1,2-a]pyridine complexes and their potential anticancer activity","volume":"126","author":"Dam","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s10495-019-01547-7","article-title":"Copper-imidazo[1,2-a]pyridines induce intrinsic apoptosis and modulate the expression of mutated p53, haem-oxygenase-1 and apoptotic inhibitory proteins in HT-29 colorectal cancer cells","volume":"24","author":"Harmse","year":"2019","journal-title":"Apoptosis"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"12491","DOI":"10.1074\/jbc.C200093200","article-title":"ATM Mediates Phosphorylation at Multiple p53 Sites, Including Ser46, in Response to Ionizing Radiation*","volume":"277","author":"Saito","year":"2002","journal-title":"J. Biol. Chem."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1039\/C4SC00384E","article-title":"A mitochondrion-targeting copper complex exhibits potent cytotoxicity against cisplatin-resistant tumor cells through multiple mechanisms of action","volume":"5","author":"Zhou","year":"2014","journal-title":"Chem. Sci."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Shao, J., Li, M., Guo, Z., Jin, C., Zhang, F., Ou, C., Xie, Y., Tan, S., Wang, Z., and Zheng, S. (2019). TPP-related mitochondrial targeting copper (II) complex induces p53-dependent apoptosis in hepatoma cells through ROS-mediated activation of Drp1. Cell Commun. Signal., 17.","DOI":"10.1186\/s12964-019-0468-6"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1124\/jpet.104.069104","article-title":"p53-Dependent Apoptotic Mechanism of a New Designer Bimetallic Compound Tri-phenyl Tin Benzimidazolethiol Copper Chloride (TPT-CuCl2): In Vivo Studies in Wistar Rats as Well as in Vitro Studies in Human Cervical Cancer Cells","volume":"311","author":"Zhu","year":"2004","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/S0021-9258(18)94247-X","article-title":"Site-specific oxidative DNA damage at polyguanosines produced by copper plus hydrogen peroxide","volume":"264","author":"Sagripanti","year":"1989","journal-title":"J. Biol. Chem."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1146\/annurev-nutr-082117-051732","article-title":"Iron and Cancer","volume":"38","author":"Torti","year":"2018","journal-title":"Annu. Rev. Nutr."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.celrep.2014.02.042","article-title":"Iron Metabolism Regulates p53 Signaling through Direct Heme-p53 Interaction and Modulation of p53 Localization, Stability, and Function","volume":"7","author":"Shen","year":"2014","journal-title":"Cell Rep."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.2353\/ajpath.2010.090249","article-title":"Iron-dependent regulation of MDM2 influences p53 activity and hepatic carcinogenesis","volume":"176","author":"Dongiovanni","year":"2010","journal-title":"Am. J. Pathol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1016\/j.biocel.2008.02.010","article-title":"p53-Mediated downregulation of H ferritin promoter transcriptional efficiency via NF-Y","volume":"40","author":"Faniello","year":"2008","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"11775","DOI":"10.1073\/pnas.1004250107","article-title":"Humans possess two mitochondrial ferredoxins, Fdx1 and Fdx2, with distinct roles in steroidogenesis, heme, and Fe\/S cluster biosynthesis","volume":"107","author":"Sheftel","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.biomaterials.2015.08.031","article-title":"Cellular localization of iron(II) polypyridyl complexes determines their anticancer action mechanisms","volume":"71","author":"Chen","year":"2015","journal-title":"Biomaterials"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.bcp.2005.11.009","article-title":"Anticancer activity of the lanthanum compound [tris(1,10-phenanthroline)lanthanum(III)]trithiocyanate (KP772; FFC24)","volume":"71","author":"Heffeter","year":"2006","journal-title":"Biochem. Pharmacol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"31663","DOI":"10.1074\/jbc.274.44.31663","article-title":"Cadmium Induces Conformational Modifications of Wild-type p53 and Suppresses p53 Response to DNA Damage in Cultured Cells*","volume":"274","author":"Mann","year":"1999","journal-title":"J. Biol. Chem."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejmech.2017.04.007","article-title":"Platinum, palladium, gold and ruthenium complexes as anticancer agents: Current clinical uses, cytotoxicity studies and future perspectives","volume":"142","author":"Rilak","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Levina, A., Chetcuti, A.R.M., and Lay, P.A. (2022). Controversial Role of Transferrin in the Transport of Ruthenium Anticancer Drugs. Biomolecules, 12.","DOI":"10.3390\/biom12091319"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1039\/b309160k","article-title":"Transferrin binding and transferrin-mediated cellular uptake of the ruthenium coordination compound KP1019, studied by means of AAS, ESI-MS and CD spectroscopy","volume":"19","author":"Pongratz","year":"2004","journal-title":"J. Anal. At. Spectrom."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s00775-010-0642-1","article-title":"Intracellular protein binding patterns of the anticancer ruthenium drugs KP1019 and KP1339","volume":"15","author":"Heffeter","year":"2010","journal-title":"J. Biol. Inorg. Chem."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1039\/b508060f","article-title":"Two dimensional separation schemes for investigation of the interaction of an anticancer ruthenium(iii) compound with plasma proteins","volume":"20","author":"Sulyok","year":"2005","journal-title":"J. Anal. At. Spectrom."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1002\/cmdc.201500127","article-title":"Rational Design of Ruthenium Complexes Containing 2,6-Bis(benzimidazolyl)pyridine Derivatives with Radiosensitization Activity by Enhancing p53 Activation","volume":"10","author":"Deng","year":"2015","journal-title":"ChemMedChem"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2307\/3576084","article-title":"Evaluation of Nitrobenzimidazoles as Hypoxic Cell Radiosensitizers","volume":"95","author":"Wright","year":"1983","journal-title":"Radiat. Res."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"12766","DOI":"10.1039\/c2dt30665d","article-title":"Ruthenium complexes containing 2,6-bis(benzimidazolyl)pyridine derivatives induce cancer cell apoptosis by triggering DNA damage-mediated p53 phosphorylation","volume":"41","author":"Li","year":"2012","journal-title":"Dalton Trans."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"4888","DOI":"10.1002\/jcp.27287","article-title":"Potentiating apoptosis and modulation of p53, Bcl2, and Bax by a novel chrysin ruthenium complex for effective chemotherapeutic efficacy against breast cancer","volume":"234","author":"Roy","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s10534-018-0117-3","article-title":"Vanadium quercetin complex attenuates mammary cancer by regulating the P53, Akt\/mTOR pathway and downregulates cellular proliferation correlated with increased apoptotic events","volume":"31","author":"Roy","year":"2018","journal-title":"BioMetals"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1124\/jpet.105.089342","article-title":"Ruthenium (II)-derived organometallic compounds induce cytostatic and cytotoxic effects on mammalian cancer cell lines through p53-dependent and p53-independent mechanisms","volume":"315","author":"Gaiddon","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1021\/acs.molpharmaceut.6b00348","article-title":"Structural Determinants of p53-Independence in Anticancer Ruthenium-Arene Schiff-Base Complexes","volume":"13","author":"Chow","year":"2016","journal-title":"Mol. Pharm."},{"key":"ref_112","first-page":"171","article-title":"Multinuclear Organometallic Ruthenium-Arene Complexes for Cancer Therapy","volume":"18","author":"Babak","year":"2018","journal-title":"Met. Ions Life Sci."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/j.ejmech.2018.08.054","article-title":"Dimetallic Ru(II) arene complexes appended on bis-salicylaldimine induce cancer cell death and suppress invasion via p53-dependent signaling","volume":"157","author":"Rahman","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jinorgbio.2019.01.019","article-title":"Anticancer activity and mechanism of bis-pyrimidine based dimetallic Ru(II)(\u03b76-p-cymene) complex in human non-small cell lung cancer via p53-dependent pathway","volume":"194","author":"Bhatti","year":"2019","journal-title":"J. Inorg. Biochem."},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Llombart, V., and Mansour, M.R. (2022). Therapeutic targeting of \u201cundruggable\u201d MYC. eBioMedicine, 75.","DOI":"10.1016\/j.ebiom.2021.103756"},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Baliza, I.R.S., Silva, S.L.R., Santos, L.d.S., Neto, J.H.A., Dias, R.B., Sales, C.B.S., Rocha, C.A.G., Soares, M.B.P., Batista, A.A., and Bezerra, D.P. (2019). Ruthenium Complexes With Piplartine Cause Apoptosis Through MAPK Signaling by a p53-Dependent Pathway in Human Colon Carcinoma Cells and Inhibit Tumor Development in a Xenograft Model. Front. Oncol., 9.","DOI":"10.3389\/fonc.2019.00582"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"104367","DOI":"10.18632\/oncotarget.22248","article-title":"Novel piplartine-containing ruthenium complexes: Synthesis, cell growth inhibition, apoptosis induction and ROS production on HCT116 cells","volume":"8","author":"Baliza","year":"2017","journal-title":"Oncotarget"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ejmech.2018.06.057","article-title":"Piperlongumine (piplartine) as a lead compound for anticancer agents\u2014Synthesis and properties of analogues: A mini-review","volume":"156","author":"Piska","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Lai, H., Zeng, D., Liu, C., Zhang, Q., Wang, X., and Chen, T. (2019). Selenium-containing ruthenium complex synergizes with natural killer cells to enhance immunotherapy against prostate cancer via activating TRAIL\/FasL signaling. Biomaterials, 219.","DOI":"10.1016\/j.biomaterials.2019.119377"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1002\/chem.201705561","article-title":"Cancer-Targeting Functionalization of Selenium-Containing Ruthenium Conjugate with Tumor Microenvironment-Responsive Property to Enhance Theranostic Effects","volume":"24","author":"Zhao","year":"2018","journal-title":"Eur. J. Chem."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"5998","DOI":"10.1158\/0008-5472.CAN-10-3211","article-title":"Human NK cells are alerted to induction of p53 in cancer cells by upregulation of the NKG2D ligands ULBP1 and ULBP2","volume":"71","author":"Textor","year":"2011","journal-title":"Cancer Res."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1039\/C8CS00570B","article-title":"Recent advances in gold\u2013NHC complexes with biological properties","volume":"48","author":"Mora","year":"2019","journal-title":"Chem. Soc. Rev."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"8786","DOI":"10.1039\/C5CS00132C","article-title":"Chemical biology of anticancer gold(iii) and gold(i) complexes","volume":"44","author":"Zou","year":"2015","journal-title":"Chem. Soc. Rev."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"12570","DOI":"10.1021\/ja804027j","article-title":"Mitochondria-Targeted Chemotherapeutics: The Rational Design of Gold(I) N-Heterocyclic Carbene Complexes That Are Selectively Toxic to Cancer Cells and Target Protein Selenols in Preference to Thiols","volume":"130","author":"Hickey","year":"2008","journal-title":"J. Am. Chem. Soc."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"8646","DOI":"10.1021\/jm201220n","article-title":"Comparative in Vitro Evaluation of N-Heterocyclic Carbene Gold(I) Complexes of the Benzimidazolylidene Type","volume":"54","author":"Rubbiani","year":"2011","journal-title":"J. Med. Chem."},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Dabiri, Y., Abu el Maaty, M.A., Chan, H.Y., W\u00f6lker, J., Ott, I., W\u00f6lfl, S., and Cheng, X. (2019). p53-Dependent Anti-Proliferative and Pro-Apoptotic Effects of a Gold(I) N-Heterocyclic Carbene (NHC) Complex in Colorectal Cancer Cells. Front. Oncol., 9.","DOI":"10.3389\/fonc.2019.00438"},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Nandy, A., Dey, S.K., Das, S., Munda, R.N., Dinda, J., and Saha, K.D. (2014). Gold (I) N-heterocyclic carbene complex inhibits mouse melanoma growth by p53 upregulation. Mol. Cancer, 13.","DOI":"10.1186\/1476-4598-13-57"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"5245","DOI":"10.1021\/jm101096x","article-title":"Preparation and characterization of amino-linked heterocyclic carbene palladium, gold, and silver complexes and their use as anticancer agents that act by triggering apoptotic cell death","volume":"54","author":"Wang","year":"2011","journal-title":"J. Med. Chem."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1093\/jnci\/89.14.1036","article-title":"Characterization of p53 and p21 functional interactions in glioma cells en route to apoptosis","volume":"89","author":"Fueyo","year":"1997","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41568-020-00308-y","article-title":"The rediscovery of platinum-based cancer therapy","volume":"21","author":"Rottenberg","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"ref_131","first-page":"471","article-title":"Understanding and improving platinum anticancer drugs--Phenanthriplatin","volume":"34","author":"Johnstone","year":"2014","journal-title":"Anticancer Res."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/nrc2167","article-title":"The resurgence of platinum-based cancer chemotherapy","volume":"7","author":"Kelland","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2174\/1568009033333727","article-title":"Mechanisms controlling sensitivity to platinum complexes: Role of p53 and DNA mismatch repair","volume":"3","author":"Manic","year":"2003","journal-title":"Curr. Cancer Drug Targets"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.bbcan.2010.07.004","article-title":"Cisplatin resistance: Preclinical findings and clinical implications","volume":"1806","author":"Tomicic","year":"2010","journal-title":"Biochim. Biophys. Acta-Rev. Cancer"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0163-7258(97)00086-7","article-title":"Role of apoptotic response in cellular resistance to cytotoxic agents","volume":"76","author":"Zunino","year":"1997","journal-title":"Pharmacol. Ther."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3904\/kjim.1999.14.1.42","article-title":"The relationship between cisplatin-induced apoptosis and p53, bcl-2 and bax expression in human lung cancer cells","volume":"14","author":"Han","year":"1999","journal-title":"Korean J. Intern. Med."},{"key":"ref_137","first-page":"698","article-title":"Independent pathways of p53 induction by cisplatin and X-rays in a cisplatin-resistant ovarian tumor cell line","volume":"58","author":"Siddik","year":"1998","journal-title":"Cancer Res."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"4552","DOI":"10.4161\/cc.22803","article-title":"Pro- and anti-apoptotic effects of p53 in cisplatin-treated human testicular cancer are cell context-dependent","volume":"11","author":"Koster","year":"2012","journal-title":"Cell Cycle"},{"key":"ref_139","first-page":"5824","article-title":"p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents","volume":"54","author":"Fan","year":"1994","journal-title":"Cancer Res."},{"key":"ref_140","first-page":"1649","article-title":"Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline","volume":"55","author":"Fan","year":"1995","journal-title":"Cancer Res."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.bcp.2007.05.001","article-title":"p53 dependent and independent sensitivity to oxaliplatin of colon cancer cells","volume":"74","author":"Toscano","year":"2007","journal-title":"Biochem. Pharmacol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"F1140","DOI":"10.1152\/ajprenal.00262.2004","article-title":"Role of p53 in cisplatin-induced tubular cell apoptosis: Dependence on p53 transcriptional activity","volume":"287","author":"Jiang","year":"2004","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"6572","DOI":"10.1074\/jbc.M707568200","article-title":"ATR-Chk2 signaling in p53 activation and DNA damage response during cisplatin-induced apoptosis","volume":"283","author":"Pabla","year":"2008","journal-title":"J. Biol. Chem."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"F1282","DOI":"10.1152\/ajprenal.00230.2007","article-title":"Activation and involvement of p53 in cisplatin-induced nephrotoxicity","volume":"293","author":"Wei","year":"2007","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"7","DOI":"10.15252\/emmm.201606230","article-title":"Reversible p53 inhibition prevents cisplatin ototoxicity without blocking chemotherapeutic efficacy","volume":"9","author":"Benkafadar","year":"2017","journal-title":"EMBO Mol. Med."},{"key":"ref_146","doi-asserted-by":"crossref","unstructured":"Maj, M.A., Ma, J., Krukowski, K.N., Kavelaars, A., and Heijnen, C.J. (2017). Inhibition of Mitochondrial p53 Accumulation by PFT-\u03bc Prevents Cisplatin-Induced Peripheral Neuropathy. Front. Mol. Neurosci., 10.","DOI":"10.3389\/fnmol.2017.00108"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"6301","DOI":"10.1039\/C4CC10409A","article-title":"Chalcoplatin, a dual-targeting and p53 activator-containing anticancer platinum(IV) prodrug with unique mode of action","volume":"51","author":"Ma","year":"2015","journal-title":"Chem. Commun."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ejmech.2018.09.008","article-title":"Novel tacrine platinum(II) complexes display high anticancer activity via inhibition of telomerase activity, dysfunction of mitochondria, and activation of the p53 signaling pathway","volume":"158","author":"Qin","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"4336","DOI":"10.1021\/acs.molpharmaceut.5b00531","article-title":"A Novel Platinum\u2013Maurocalcine Conjugate Induces Apoptosis of Human Glioblastoma Cells by Acting through the ROS-ERK\/AKT-p53 Pathway","volume":"12","author":"Aroui","year":"2015","journal-title":"Mol. Pharm."},{"key":"ref_150","doi-asserted-by":"crossref","unstructured":"Ibrahim, A.A., Kareem, M.M., Al-Noor, T.H., Al-Muhimeed, T., AlObaid, A.A., Albukhaty, S., Sulaiman, G.M., Jabir, M., Taqi, Z.J., and Sahib, U.I. (2021). Pt(II)-Thiocarbohydrazone Complex as Cytotoxic Agent and Apoptosis Inducer in Caov-3 and HT-29 Cells through the P53 and Caspase-8 Pathways. Pharmaceuticals, 14.","DOI":"10.3390\/ph14060509"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.molstruc.2019.04.119","article-title":"Spectroscopic exploration of binding of new imidazolium-based palladium(II) saldach complexes with CT-DNA as anticancer agents against HER2\/neu overexpression","volume":"1191","author":"Alfaifi","year":"2019","journal-title":"J. Mol. Struct."},{"key":"ref_152","first-page":"457","article-title":"Apoptosis-inducing Effect of a Palladium(II) Complex-[PdCl(terpy)](sac).2H2O] on Ehrlich Ascites Carcinoma (EAC) in Mice","volume":"30","author":"Ulukaya","year":"2016","journal-title":"In Vivo"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1021\/cb400070a","article-title":"Organometallic Iridium(III) Anticancer Complexes with New Mechanisms of Action: NCI-60 Screening, Mitochondrial Targeting, and Apoptosis","volume":"8","author":"Hearn","year":"2013","journal-title":"ACS Chem. Biol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1039\/C4MT00112E","article-title":"A dual-targeting, apoptosis-inducing organometallic half-sandwich iridium anticancer complex\u2020","volume":"6","author":"Novohradsky","year":"2014","journal-title":"Metallomics"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1021\/acsabm.9b01156","article-title":"Aliphatic Group-Tethered Iridium Complex as a Theranostic Agent against Malignant Melanoma Metastasis","volume":"3","author":"Wu","year":"2020","journal-title":"ACS Appl. Bio Mater."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1046\/j.1365-2133.1999.02905.x","article-title":"Predictive value of serum S100B for monitoring patients with metastatic melanoma during chemotherapy and\/or immunotherapy","volume":"140","author":"Hauschild","year":"1999","journal-title":"Br. J. Dermatol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"35037","DOI":"10.1074\/jbc.M104379200","article-title":"Inhibition of p53 Transcriptional Activity by the S100B Calcium-binding Protein*","volume":"276","author":"Lin","year":"2001","journal-title":"J. Biol. Chem."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"2874","DOI":"10.2174\/0929867323666160321121138","article-title":"Why Antidiabetic Vanadium Complexes are Not in the Pipeline of \u201cBig Pharma\u201d Drug Research? A Critical Review","volume":"23","author":"Scior","year":"2016","journal-title":"Curr. Med. Chem."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1016\/j.jinorgbio.2006.08.016","article-title":"Vanadium in diabetes: 100 years from Phase 0 to Phase I","volume":"100","author":"Thompson","year":"2006","journal-title":"J. Inorg. Biochem."},{"key":"ref_160","doi-asserted-by":"crossref","unstructured":"Kowalski, S., Wyrzykowski, D., and Inkielewicz-St\u0119pniak, I. (2020). Molecular and Cellular Mechanisms of Cytotoxic Activity of Vanadium Compounds against Cancer Cells. Molecules, 25.","DOI":"10.3390\/molecules25071757"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1055\/a-1235-5565","article-title":"Induction of Cell Cycle Arrest in MKN45 Cells after Schiff Base Oxovanadium Complex Treatment Using Changes in Gene Expression of CdC25 and P53","volume":"70","author":"Mirjalili","year":"2020","journal-title":"Drug Res."},{"key":"ref_162","doi-asserted-by":"crossref","unstructured":"Kowalski, S., Wyrzykowski, D., Hac, S., Rychlowski, M., Radomski, M.W., and Inkielewicz-Stepniak, I. (2019). New Oxidovanadium(IV) Coordination Complex Containing 2-Methylnitrilotriacetate Ligands Induces Cell Cycle Arrest and Autophagy in Human Pancreatic Ductal Adenocarcinoma Cell Lines. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20020261"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.cbi.2015.09.017","article-title":"Study of antitumor effect of selected vanadium and molybdenum organometallic complexes in human leukemic T-cells","volume":"242","author":"Havelek","year":"2015","journal-title":"Chem. Biol. Interact."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"15258","DOI":"10.3390\/molecules190915258","article-title":"Current and potential applications of bismuth-based drugs","volume":"19","author":"Keogan","year":"2014","journal-title":"Molecules"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1016\/j.ccr.2007.03.003","article-title":"Biocoordination chemistry of bismuth: Recent advances","volume":"251","author":"Yang","year":"2007","journal-title":"Coord. Chem. Rev."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"12037","DOI":"10.1039\/D0CS00031K","article-title":"Medicinal chemistry and biomedical applications of bismuth-based compounds and nanoparticles","volume":"50","author":"Griffith","year":"2021","journal-title":"Chem. Soc. Rev."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"729","DOI":"10.2174\/0929867324666171003113540","article-title":"Recent Research Trends on Bismuth Compounds in Cancer Chemoand Radiotherapy","volume":"26","author":"Kowalik","year":"2019","journal-title":"Curr. Med. Chem."},{"key":"ref_168","doi-asserted-by":"crossref","unstructured":"Khan, M.H., Cai, M., Li, S., Zhang, Z., Zhang, J., Wen, X., Sun, H., Liang, H., and Yang, F. (2019). Developing a binuclear multi-target Bi(III) complex by optimizing 2-acetyl-3-ethylpyrazine thiosemicarbazides. Eur. J. Med. Chem., 182.","DOI":"10.1016\/j.ejmech.2019.111616"},{"key":"ref_169","doi-asserted-by":"crossref","unstructured":"Esmail, S.A.A., Shamsi, M., Chen, T., and Al-asbahy, W.M. (2019). Design, synthesis and characterization of tin-based cancer chemotherapy drug entity: In vitro DNA binding, cleavage, induction of cancer cell apoptosis by triggering DNA damage-mediated p53 phosphorylation and molecular docking. Appl. Organomet. Chem., 33.","DOI":"10.1002\/aoc.4651"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"17478","DOI":"10.1074\/jbc.M111.231639","article-title":"Mutant p53 protein is targeted by arsenic for degradation and plays a role in arsenic-mediated growth suppression","volume":"286","author":"Yan","year":"2011","journal-title":"J. Biol. Chem."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/10\/2834\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:38:23Z","timestamp":1760125103000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/10\/2834"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,19]]},"references-count":170,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,5]]}},"alternative-id":["cancers15102834"],"URL":"https:\/\/doi.org\/10.3390\/cancers15102834","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,19]]}}}